MARKET

KLRS

KLRS

Kalaris Therapeutics Inc
NASDAQ
5.49
+0.10
+1.86%
Opening 09:52 03/30 EDT
OPEN
5.43
PREV CLOSE
5.39
HIGH
5.49
LOW
5.43
VOLUME
2.19K
TURNOVER
--
52 WEEK HIGH
12.26
52 WEEK LOW
2.140
MARKET CAP
125.88M
P/E (TTM)
-1.9296
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at KLRS last week (0323-0327)?
Weekly Report · 3h ago
Top Kalaris Therapeutics Executive Quietly Unloads Company Shares
TipRanks · 6d ago
Kalaris Therapeutics Chief Accounting Officer Brett Hagen disposes of USD 12,869 of common shares
Reuters · 6d ago
Weekly Report: what happened at KLRS last week (0316-0320)?
Weekly Report · 03/23 10:31
Kalaris Therapeutics, Inc. GAAP EPS of -$2.85
Seeking Alpha · 03/17 19:50
Kalaris Therapeutics: Early TH103 Data in nAMD Support Buy Rating and Favorable Risk/Reward Despite Manufacturing Hurdles
TipRanks · 03/17 16:15
Kalaris Therapeutics Q4 EPS $(0.44) Beats $(0.56) Estimate
Benzinga · 03/17 12:13
Kalaris Therapeutics reports FY25 EPS ($2.85), consensus ($3.70)
TipRanks · 03/17 12:05
More
About KLRS
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).

Webull offers Kalaris Therapeutics Inc stock information, including NASDAQ: KLRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KLRS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KLRS stock methods without spending real money on the virtual paper trading platform.